• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在正常和后肢缺血模型中使用重组碱性成纤维细胞生长因子与去端肽胶原进行血管生成研究。

Angiogenesis Using Recombinant Basic Fibroblast Growth Factor With Atelocollagen in Normal and Hind Limb Ischemia Models.

作者信息

Kotani Atsushi, Watanabe Shin, Kato Takao, Kikuchi Takayuki, Toya Keiji, Hori Katsuhiko, Minobe Noriko, Musumi Kaori, Kimura Yasuko, Nagai Yoji, Yoshimura Jun, Kawamata Hirofumi, Yanishi Kenji, Matoba Satoaki

机构信息

FEF Pharmaceutical Co., Ltd. Tokyo Japan.

Research Center, EPS Innovative Medicine Co., Ltd. Tokyo Japan.

出版信息

Circ Rep. 2025 Mar 15;7(5):372-378. doi: 10.1253/circrep.CR-25-0011. eCollection 2025 May 9.

DOI:10.1253/circrep.CR-25-0011
PMID:40352133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12061500/
Abstract

BACKGROUND

Basic fibroblast growth factor (bFGF) is an angiogenic factor with a short half-life. Because recombinant bFGF is in clinical use, we hypothesized that the localization of recombinant bFGF with atelocollagen would have angiogenic effects at the injection site in normal and hind limb ischemic animal models.

METHODS AND RESULTS

We administered the recombinant bFGF with atelocollagen intramuscularly to hind limbs in normal rabbits or in a mouse model of femoral artery ligation to explore the pharmacological action for ischemia. We evaluated blood flow in the ischemic/normal limb using laser speckle perfusion imaging and the density of blood vessels by pathological examination. At the administration site in normal rabbits, a significant increase in the number of blood vessels was noted at 14 days post-administration of recombinant bFGF with atelocollagen compared with saline or atelocollagen alone. In mice with femoral artery ligation, blood flow and vessels in the ischemic hind limb increased at 2 weeks after injection and more at 4 weeks after injection, and the effect was most significant in mice administered 100 μg of recombinant bFGF with 3% of atelocollagen.

CONCLUSIONS

Intramuscular administration of recombinant bFGF with atelocollagen induced angiogenesis between 2 and 4 weeks in both normal and ischemic hind limbs.

摘要

背景

碱性成纤维细胞生长因子（bFGF）是一种半衰期较短的血管生成因子。由于重组bFGF已在临床应用，我们推测重组bFGF与去端胶原蛋白的定位在正常和后肢缺血动物模型的注射部位会产生血管生成作用。

方法与结果

我们将重组bFGF与去端胶原蛋白肌肉注射到正常兔的后肢或股动脉结扎小鼠模型中，以探索其对缺血的药理作用。我们使用激光散斑灌注成像评估缺血/正常肢体的血流，并通过病理检查评估血管密度。在正常兔的给药部位，与单独注射生理盐水或去端胶原蛋白相比，在注射重组bFGF与去端胶原蛋白后14天，血管数量显著增加。在股动脉结扎的小鼠中，缺血后肢的血流和血管在注射后2周增加，在注射后4周增加更多，并且在给予100μg重组bFGF与3%去端胶原蛋白的小鼠中效果最显著。

结论

肌肉注射重组bFGF与去端胶原蛋白在正常和缺血后肢均可在2至4周内诱导血管生成。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/ebc326eb6635/circrep-7-372-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/4f55838cc109/circrep-7-372-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/bc08a4eefa03/circrep-7-372-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/731a63f09ebe/circrep-7-372-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/ebc326eb6635/circrep-7-372-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/4f55838cc109/circrep-7-372-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/bc08a4eefa03/circrep-7-372-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/731a63f09ebe/circrep-7-372-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f2f/12061500/ebc326eb6635/circrep-7-372-g004.jpg

相似文献

1
Angiogenesis Using Recombinant Basic Fibroblast Growth Factor With Atelocollagen in Normal and Hind Limb Ischemia Models.在正常和后肢缺血模型中使用重组碱性成纤维细胞生长因子与去端肽胶原进行血管生成研究。
Circ Rep. 2025 Mar 15;7(5):372-378. doi: 10.1253/circrep.CR-25-0011. eCollection 2025 May 9.
2
First-in-Man Clinical Pilot Study Showing the Safety and Efficacy of Intramuscular Injection of Basic Fibroblast Growth Factor With Atelocollagen Solution for Critical Limb Ischemia.首例人体临床初步研究显示：碱性成纤维细胞生长因子联合去端肽胶原溶液肌内注射治疗肢体严重缺血安全有效。
Circ J. 2018 Dec 25;83(1):217-223. doi: 10.1253/circj.CJ-18-0815. Epub 2018 Nov 9.
3
Coadministration of adipose-derived stem cells and control-released basic fibroblast growth factor facilitates angiogenesis in a murine ischemic hind limb model.脂肪来源干细胞与控释碱性成纤维细胞生长因子联合给药促进小鼠缺血后肢模型中的血管生成。
J Vasc Surg. 2016 Dec;64(6):1825-1834.e1. doi: 10.1016/j.jvs.2015.09.054. Epub 2015 Nov 17.
4
Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia.在兔后肢缺血模型中，含碱性成纤维细胞生长因子的明胶水凝胶促进血管生成
Heart Vessels. 2007 Mar;22(2):104-8. doi: 10.1007/s00380-006-0934-0. Epub 2007 Mar 23.
5
Hyperbaric oxygen induces basic fibroblast growth factor and hepatocyte growth factor expression, and enhances blood perfusion and muscle regeneration in mouse ischemic hind limbs.高压氧可诱导碱性成纤维细胞生长因子和肝细胞生长因子的表达，并增强小鼠缺血后肢的血液灌注和肌肉再生。
Circ J. 2007 Mar;71(3):405-11. doi: 10.1253/circj.71.405.
6
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.血管内皮生长因子与碱性成纤维细胞生长因子对体内血管生成的协同作用。
Circulation. 1995 Nov 1;92(9 Suppl):II365-71. doi: 10.1161/01.cir.92.9.365.
7
Angiogenesis. Angiogenic therapy using fibroblast growth factors and vascular endothelial growth factors for ischemic vascular lesions.血管生成。使用成纤维细胞生长因子和血管内皮生长因子对缺血性血管病变进行血管生成治疗。
Jpn Heart J. 1996 May;37(3):285-300. doi: 10.1536/ihj.37.285.
8
Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor.在兔急性下肢缺血模型中，通过体内给予重组碱性成纤维细胞生长因子增强血管生成和侧支生长：碱性成纤维细胞生长因子的剂量反应效应
J Vasc Surg. 1992 Aug;16(2):181-91.
9
Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation.同时应用碱性成纤维细胞生长因子和肝细胞生长因子以增强血管形成。
J Vasc Surg. 2005 Jan;41(1):82-90. doi: 10.1016/j.jvs.2004.10.029.
10
Functional outcome of new blood vessel growth into ischemic skeletal muscle.新生血管长入缺血骨骼肌的功能转归
J Vasc Surg. 2001 Dec;34(6):1096-102. doi: 10.1067/mva.2001.117889.

本文引用的文献

1
First-in-Man Clinical Pilot Study Showing the Safety and Efficacy of Intramuscular Injection of Basic Fibroblast Growth Factor With Atelocollagen Solution for Critical Limb Ischemia.首例人体临床初步研究显示：碱性成纤维细胞生长因子联合去端肽胶原溶液肌内注射治疗肢体严重缺血安全有效。
Circ J. 2018 Dec 25;83(1):217-223. doi: 10.1253/circj.CJ-18-0815. Epub 2018 Nov 9.
2
Autologous Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 Positive Cell Transplantation for Hemodialysis Patients with Critical Limb Ischemia: A Prospective Phase II Clinical Trial.自体粒细胞集落刺激因子动员的外周血 CD34 阳性细胞移植治疗血液透析合并严重肢体缺血患者：一项前瞻性 II 期临床试验。
Stem Cells Transl Med. 2018 Nov;7(11):774-782. doi: 10.1002/sctm.18-0104. Epub 2018 Jul 30.
3
Outcome From a Randomized Controlled Clinical Trial　- Improvement of Peripheral Arterial Disease by Granulocyte Colony-Stimulating Factor-Mobilized Autologous Peripheral-Blood-Mononuclear Cell Transplantation (IMPACT).随机对照临床试验结果——粒细胞集落刺激因子动员自体外周血单个核细胞移植（IMPACT）改善外周动脉疾病。
Circ J. 2018 Jul 25;82(8):2165-2174. doi: 10.1253/circj.CJ-17-1220. Epub 2018 Jun 7.
4
Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan.日本骨髓源性细胞疗法治疗严重肢体缺血的长期临床结果调查。
Circ J. 2018 Mar 23;82(4):1168-1178. doi: 10.1253/circj.CJ-17-0510. Epub 2018 Jan 30.
5
Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia.使用明胶水凝胶持续释放碱性成纤维细胞生长因子治疗严重肢体缺血患者的安全性和有效性。
Heart Vessels. 2016 May;31(5):713-21. doi: 10.1007/s00380-015-0677-x. Epub 2015 Apr 11.
6
Phase II clinical trial of CD34+ cell therapy to explore endpoint selection and timing in patients with critical limb ischemia.CD34+细胞疗法治疗严重肢体缺血患者的II期临床试验，以探索终点选择和时机。
Circ J. 2014;78(2):490-501. doi: 10.1253/circj.cj-13-0864. Epub 2013 Nov 21.
7
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.2000 年和 2010 年全球外周动脉疾病患病率和危险因素的估计值比较：系统评价和分析。
Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1.
8
Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.粒细胞集落刺激因子动员的 CD34(+) 细胞经肌肉内移植治疗严重肢体缺血患者：一项 I/IIa 期、多中心、单盲、剂量递增临床试验。
Stem Cells. 2009 Nov;27(11):2857-64. doi: 10.1002/stem.207.
9
Selective and sustained delivery of basic fibroblast growth factor (bFGF) for treatment of peripheral arterial disease: results of a phase I trial.
Eur J Vasc Endovasc Surg. 2009 Jul;38(1):71-5. doi: 10.1016/j.ejvs.2009.02.005. Epub 2009 Mar 26.
10
A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study.一种通过可生物降解的明胶水凝胶持续释放碱性成纤维细胞生长因子，用于治疗严重肢体缺血患者的治疗性血管生成新方法：I-IIa期研究的初步报告
Circ J. 2007 Aug;71(8):1181-6. doi: 10.1253/circj.71.1181.